Holen Sie sich die Stockscreener-App
3.8506
3.23%
0.1206
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
CRVO Stock Price, Quote & Chart | CERVOMED INC (NASDAQ:CRVO) - ChartMill
CervoMed (CRVO) outlines 2026 virtual meeting, board slate and pay plan vote - Stock Titan
CRVO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CRVO (CervoMed) posts wider than expected Q4 2025 loss even as shares notch mild daily gains.Crowd Risk Alerts - Newser
CRVO Maintained by D. Boral Capital -- Price Target Steady at $3 - GuruFocus
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results - TipRanks
CRVO (CervoMed Inc.) reports wider-than-expected Q4 2025 loss driven by elevated clinical research spending.Decline Phase - Cổng thông tin điện tử Tỉnh Sơn La
Neflamapimod MRI data in dementia with Lewy bodies from CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed (CRVO) Shows Promise in DLB Treatment with Neflamapimod - GuruFocus
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - ChartMill
What should investors watch for CervoMed (CRVO) stock (Smart Money Exits) 2026-04-20Public Sentiment - Cổng thông tin điện tử tỉnh Lào Cai
Is CervoMed (CRVO) stock a good candidate for diversification (Investor Concern) 2026-04-18Community Pattern Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Operating cash flow per share of CervoMed Inc. – FWB:DP8 - TradingView — Track All Markets
CRVO Should I Buy - Intellectia AI
CRVO.O PE Ratio & Valuation, Is CRVO.O Overvalued - Intellectia AI
CRVO.O Forecast — Price Prediction for 2026. Should I Buy CRVO.O? - Intellectia AI
Buyout Rumor: Does CervoMed Inc have strong fundamentalsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
CRVO.O Technical Analysis & Stock Price Forecast - Intellectia AI
CRVO.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lewy Body Dementia Market: Accelerating Growth And Pipeline Impact By 2034 Delveinsight Cognition Therapeutics, Keiferx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Mena FN
Lewy Body Dementia Market: Accelerating Growth and Pipeline - openPR.com
CervoMed Inc. prepares Phase 3 trial after CEO engages on advancing dementia biomarkers - Traders Union
CervoMed (CRVO) Maintains "Buy" Rating with $31 Price Target | C - GuruFocus
CervoMed Inc. Provides Neflamapimod Clinical Program Update and Announces Participation at 2026 Lewy Body Dementia Association Annual Meeting - Minichart
Is CervoMed (CRVO) Stock Lagging the Market | Price at $3.79, Down 1.38%Community Breakout Alerts - Newser
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia - TipRanks
AWM-owned funds hold 405,165 shares in CervoMed (CRVO) — 4.2% stake - Stock Titan
Form 8-KCurrent report - ADVFN
CervoMed Inc. Announces Neflamapimod Clinical Trial Updates and MRI Findings at Lewy Body Dementia Association Meeting - Quiver Quantitative
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - ChartMill
CRVO PE Ratio & Valuation, Is CRVO Overvalued - Intellectia AI
CRVO.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CRVO News & Events - Intellectia AI
CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com
CRVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
CRVO Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Buy: How do insiders feel about CervoMed IncPrice Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
CervoMed (CRVO)’s Q4 results feature advancements in its neflamapimod program for dementia Lewy bodies (DLB) - MSN
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB) - Insider Monkey
CEO Change: Is CervoMed Inc stock overvalued or fairly priced2026 Technicals & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Top 5 Stocks Under $5 That Could Triple - insidermonkey.com
CervoMed Posts Investor Presentation Under Regulation FD Disclosure - TipRanks
CRVO: Phase III DLB trial launches this year, leveraging biomarker-driven selection and robust phase II data - TradingView
CervoMed (NASDAQ: CRVO) furnishes updated investor presentation via 8-K - Stock Titan
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):